Aibing Xu

2.4k total citations
10 papers, 179 citations indexed

About

Aibing Xu is a scholar working on Hepatology, Molecular Biology and Oncology. According to data from OpenAlex, Aibing Xu has authored 10 papers receiving a total of 179 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hepatology, 4 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Aibing Xu's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Cancer Mechanisms and Therapy (3 papers) and Cancer-related molecular mechanisms research (2 papers). Aibing Xu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Cancer Mechanisms and Therapy (3 papers) and Cancer-related molecular mechanisms research (2 papers). Aibing Xu collaborates with scholars based in China. Aibing Xu's co-authors include Yuxian Bai, Siyuan Tian, Li Bai, Guoliang Shao, Meili Sun, Jian Wu, Yilong Zhou, Baiyong Li, Hongyu Cai and Yuan Zhou and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Frontiers in Immunology.

In The Last Decade

Aibing Xu

10 papers receiving 178 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aibing Xu China	7	82	74	47	40	39	10	179
Sunyoung S. Lee United States	10	112 1.4×	99 1.3×	79 1.7×	43 1.1×	48 1.2×	43	265
Kazuki Maesaka Japan	7	138 1.7×	84 1.1×	37 0.8×	45 1.1×	43 1.1×	12	210
Wen‐Bin Ding China	6	67 0.8×	49 0.7×	75 1.6×	28 0.7×	51 1.3×	11	199
Roger Esteban-Fabró Spain	4	70 0.9×	61 0.8×	40 0.9×	23 0.6×	71 1.8×	8	152
Derek-Zhen Xu China	5	124 1.5×	91 1.2×	21 0.4×	47 1.2×	24 0.6×	6	171
Katsumi Terashita Japan	7	77 0.9×	55 0.7×	67 1.4×	32 0.8×	33 0.8×	8	189
Maria Aurelia Barbera Italy	9	104 1.3×	134 1.8×	69 1.5×	50 1.3×	53 1.4×	19	284
Nieves Martínez Lago Spain	8	29 0.4×	121 1.6×	40 0.9×	29 0.7×	33 0.8×	44	165
Helena Taflin Sweden	10	45 0.5×	166 2.2×	48 1.0×	60 1.5×	58 1.5×	25	253
Ningyuan Wen China	7	110 1.3×	62 0.8×	71 1.5×	14 0.3×	66 1.7×	22	241

Countries citing papers authored by Aibing Xu

Since Specialization

Citations

This map shows the geographic impact of Aibing Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aibing Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aibing Xu more than expected).

Fields of papers citing papers by Aibing Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aibing Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aibing Xu. The network helps show where Aibing Xu may publish in the future.

Co-authorship network of co-authors of Aibing Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Aibing Xu. A scholar is included among the top collaborators of Aibing Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aibing Xu. Aibing Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Zhou, Jin, Jie Fan, Shunchang Jiao, et al.. (2024). LBA40 Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Annals of Oncology. 35. S1231–S1231. 3 indexed citations

Qiao, Qian, Chun Han, Sisi Ye, et al.. (2023). The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial. Frontiers in Immunology. 14. 1238667–1238667. 30 indexed citations

Xu, Wei, et al.. (2023). Development and Validation of Nomograms to Predict the Prognosis of Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial Chemoembolization. Clinical Medicine Insights Oncology. 17. 1373299138–1373299138. 1 indexed citations

Bai, Li, Meili Sun, Aibing Xu, et al.. (2021). Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.. Journal of Clinical Oncology. 39(15_suppl). 4101–4101. 29 indexed citations

Tian, Siyuan, et al.. (2020). Expression Level and Clinical Significance of NKILA in Human Cancers: A Systematic Review and Meta‐Analysis. BioMed Research International. 2020(1). 4540312–4540312. 8 indexed citations

Yu, Yang, Qiaoyu Chen, Xunlei Zhang, et al.. (2020). Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression. Cancer Science. 111(7). 2297–2309. 19 indexed citations

Li, Qiu, Shukui Qin, Shanzhi Gu, et al.. (2020). Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.. Journal of Clinical Oncology. 38(15_suppl). 4507–4507. 24 indexed citations

Bi, Feng, Shukui Qin, Shanzhi Gu, et al.. (2020). Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.. Journal of Clinical Oncology. 38(15_suppl). 4506–4506. 32 indexed citations

Tian, Siyuan, et al.. (2014). Expression of leucine aminopeptidase 3 (LAP3) correlates with prognosis and malignant development of human hepatocellular carcinoma (HCC).. PubMed. 7(7). 3752–62. 28 indexed citations

10.

Wu, Zhijun, et al.. (2011). [Combined three-dimensional conformal radiotherapy plus transcatheter arterial chemoembolization and surgical intervention for portal vein tumor thrombus in patients with hepatocellular carcinoma].. PubMed. 91(40). 2841–4. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact